The Epigenetic Regulation of OLIG2 by Histone Demethylase KDM6B in Glioma Cells

Gliomas are common tumors that occur in the brain, accounting for 80% of all malignant brain tumors. Oligodendrocyte transcription factor 2 (OLIG2) is a key transcription factor and strongly expressed in gliomas, which drives proliferation and invasion of glioma cells. Our previous studies have show...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular neuroscience 2022-05, Vol.72 (5), p.939-946
Main Authors: Sui, Aixia, Han, Biaogang, Ren, Wenjun, He, Weiliang, Gao, Chao, Han, Xiaohui, Liu, Shifeng, Zhang, Yan, Qi, Xueling, Guo, Xiaoqiang
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Brain
Brain cancer
Brain Neoplasms - genetics
Brain tumors
Cell Biology
Cell proliferation
Chromatin
Demethylation
Drug development
Enzymatic activity
Epigenesis, Genetic
Epigenetics
Gene expression
Glioma
Glioma - genetics
Glioma cells
Histone Demethylases - genetics
Histones
Humans
Immunoprecipitation
Jumonji Domain-Containing Histone Demethylases - genetics
Lysine
Neurochemistry
Neurological diseases
Neurology
Neurosciences
Olig2 protein
Oligodendrocyte Transcription Factor 2 - genetics
Proteins
Proteomics
Regulatory mechanisms (biology)
Transcription factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gliomas are common tumors that occur in the brain, accounting for 80% of all malignant brain tumors. Oligodendrocyte transcription factor 2 (OLIG2) is a key transcription factor and strongly expressed in gliomas, which drives proliferation and invasion of glioma cells. Our previous studies have shown that histone lysine (K) demethylase 6B (KDM6B) promotes glioma development. The data also showed that OLIG2 content was positively correlated with KDM6B. Based on this, we proposed that KDM6B may play biological roles by regulating OLIG2 expression. Subsequently, many experiments were performed including specific inhibitor treatment, gene knockdown, and chromatin immunoprecipitation (ChIP) array. These results indicated that inhibition of KDM6B enzymatic activity with GSK-J4 reduces OLIG2 gene expression and protein content. The KDM6B knockdown experiment yielded similar results, that is, it reduces the mRNA and protein level of OLIG2 in glioma cells. ChIP assay showed that the promoter of OLIG2 can be bound by KDM6B, which catalyzes the demethylation of H3K27me3 and increases the expression of OLIG2 . This study reveals a new regulatory mechanism of OLIG2 by KDM6B, which has important implications for the future development of drugs for gliomas and other neurological diseases.
ISSN:0895-8696
1559-1166
DOI:10.1007/s12031-022-01976-1